Mean Corpuscular Volume (MCV) to White Blood Cell (WBC) Count Ratio as a Clinical Predictor of Response to Thiopurine Medications in Patients with Inflammatory Bowel Disease: ACG IBD Research Award

Deising, Adam; Betteridge, John; Maydonovitch, Corinne; Veerappan, Ganesh R.

doi:10.14309/00000434-201210001-01679

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, complete blood cell count with differential is done routinely in patients with IBD with a laboratory cost of $85. The ratio of mean corpuscular volume (MCV) to white blood cell count (WBC) or, MCV/WBC ratio, has been proposed as a reliable and inexpensive surrogate for monitoring thiopurine efficacy, although this has not been adequately studied and has not been evaluated in children with IBD (17,18). Therefore, we designed this study to determine whether MCV/WBC ratio is associated with thiopurine therapy efficacy among pediatric patients with IBD.…”

Section: What Is Newmentioning

confidence: 99%

Mean Corpuscular Volume to White Blood Cell Ratio for Thiopurine Monitoring in Pediatric Inflammatory Bowel Disease

Kandavel¹,

Eder²,

Newman³

et al. 2019

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

Objectives:Thiopurines, commonly used to treat inflammatory bowel disease, cause lymphopenia and red blood cell macrocytosis, requiring therapeutic monitoring. Mean corpuscular volume/white blood cell (MCV/WBC) ratio has been proposed as a surrogate for therapeutic monitoring. Our aim was to investigate MCV/WBC ratio for assessing clinical response to thiopurines among pediatric patients with inflammatory bowel disease.Methods:We performed a retrospective cross-sectional study at a tertiary care center using laboratory results and standardized physician global assessments (PGA) among pediatric patients taking thiopurines. Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), fecal calprotectin, and 6-thioguanine nucleotides were assessed when available. The primary outcome was association between MCV/WBC ratio and clinical remission assessed by ESR, CRP, calprotectin, or PGA. We also used a composite outcome requiring all available data to be normal. Analyses were limited to 1 occurrence per patient, >60 days after starting thiopurine, and comparators were required to be within 14 days of one another.Results:A total of 471 patients met inclusion criteria. MCV/WBC ratio poorly predicted quiescent disease as defined by PGA (area under receiver operating characteristic curve [AuROC] 0.55, 95% confidence interval [CI] 0.43–0.66). MCV/WBC ratio better predicted quiescent disease defined as normal CRP (AuROC 0.64, 95% CI 0.58–0.70) or normal ESR (AuROC 0.59, 95% CI 0.52–0.66). When the composite outcome measure was used, MCV/WBC ratio had an AuROC of 0.65 (95% CI 0.59–0.70), indicating it is reasonably accurate in discriminating between clinical remission and active disease.Conclusions:MCV/WBC ratio is a noninferior, easy, and low-cost alternative to thiopurine metabolite monitoring.

show abstract

Section: What Is Newmentioning

confidence: 99%